FAA Proposes Allowing Pilots on Non-Insulin Diabetes Medications to Obtain Medical Certificates Without Special Issuance

The Federal Aviation Administration has proposed changing its medical certification rules to let pilots whose diabetes is controlled with non-insulin medications obtain first-, second-, or third-class medical certificates without going through the agency's Special Issuance process. The proposed rule is scheduled for publication in the Federal Register on Friday, opening a 30-day public comment period.

Under current regulations, diabetes requiring insulin or another hypoglycemic drug is treated as a specifically disqualifying condition. Pilots on non-insulin medications may still qualify, but aviation medical examiners must generally defer those applications to the FAA for Special Issuance review. The proposed rule would remove non-insulin medications from that disqualifying provision, letting qualified applicants be evaluated under the FAA's general medical standards so examiners can issue certificates at the time of examination.

The FAA estimates the change would affect approximately 3,000 cases per year that could move to direct examiner certification, plus another 1,200 cases currently handled through Special Issuance that could potentially transition to examiner-managed certification. Over five years, the agency projects applicants would save between $39.7 million and $80.2 million in labor costs. As part of its safety review, the FAA examined 51 fatal accidents from 2008 through 2025 involving pilots reported to be using non-insulin diabetes medications, determining that diabetes, related complications, or diabetes medication were unlikely to have contributed to 50 of those accidents.

"The availability of numerous new diabetes medication classes and other non-insulin treatments has substantially improved disease management," the FAA stated in the proposed rule. The agency noted that its existing diabetes standard dates to 1959 and that advances in treatment have reduced severe complications including cardiovascular events and hypoglycemia. The proposal would not change requirements for pilots whose diabetes is managed with insulin, who would continue to require Special Issuance authorization, and non-insulin cases could still be denied or deferred case-by-case if the FAA or an examiner determines the condition or treatment could interfere with safe exercise of pilot privileges.

This proposal is an example of medical standards being revised as treatment options evolve rather than as a response to a safety incident: the FAA points to a 1959-era diabetes standard and to newer non-insulin drug classes that it says have cut complications like cardiovascular events and hypoglycemia. Special Issuance review exists to let the FAA evaluate conditions that fall outside a standard's plain text, so removing a class of cases from that queue is really a statement that the underlying medical risk has shifted enough to fit ordinary general standards instead.

For the pool of certificated and prospective pilots on non-insulin diabetes treatment, the practical effect is a faster, cheaper path to certification through examiners rather than a multi-step federal review, with the FAA's own labor-cost savings estimate as the measure of how much friction that removes. The agency's case-by-case denial and deferral authority stays intact, so this is a change in default pathway rather than a relaxation of the underlying medical bar.

The rule is not final: the 30-day comment window that opens with Friday's Federal Register publication is the next milestone, and the volume and substance of comments from pilot groups, examiners and medical advisors will determine whether the FAA's case estimates and safety findings hold up before a final rule is issued.